Cetrorelix 78+78

Phase 3Small molecule

Cetrorelix 78+78 is one of 47 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaActive, not recruiting

HypertrophyActive, not recruiting

Benign Prostatic HyperplasiaPhase 3

Active, not recruiting

HypertrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

110 competitors in Benign Prostatic Hyperplasia

#DrugCompanyPhaseTrials

Levitra

Bayer

Phase 3

1 2

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

2 3

Tamsulosin OCAS

Astellas

Phase 3

5 4

Botox

AbbVie

Phase 3

2 5

Evista

Eli Lilly

Phase 2

1 6

Drug Therapy

MMassachusetts General Hospital

Phase 3

1 7

Botox

RRevance Therapeutics, Inc.

Phase 2

3 8

Firmagon

Ferring

Phase 2

2 9

Viagra

VViatris Specialty LLC

Phase 2

1 10

Zesly

MMezzion Pharma Co. Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertrophy1 trial

Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Completed·AAEterna Zentaris·Phase 3·NCT00663858·420 enrolled

Benign Prostatic Hyperplasia1 trial

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

Completed·AAEterna Zentaris·Phase 3·NCT00670306·528 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cetrorelix 78+78. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cetrorelix 78+78 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cetrorelix 78+78. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AEterna Zentaris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAEterna Zentaris

Cetrorelix 78+78

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertrophy1 trial

Benign Prostatic Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News